Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers

References

• Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297–328
   PubMed Web of Science ®Google Scholar
• Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995;5:239–44
   PubMedGoogle Scholar
• Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352:1331–6
   PubMed Web of Science ®Google Scholar
• Salzman C. Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association. Washington, DC, APA, 1990
   Google Scholar
• Cluydts R, De Roeck J, Schotte C. Comparative study on the residual daytime effects of flunitrazepam, triazolam, and placebo in healthy volunteers. Acta Ther 1986;12:205–17
   Google Scholar
• Mintzer MZ, Frey JM, Yingling JE, Griffiths RR. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol 1997;8:561–74
   PubMed Web of Science ®Google Scholar
• Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996;16:146–57
   PubMed Web of Science ®Google Scholar
• Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol. 2000;20:328–37
   PubMed Web of Science ®Google Scholar
• Rothschild AJ. Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature. J Clin Psychiatry 1992 Dec;53 Suppl:69–79
   Google Scholar
• Foster AC, Pelleymounter MA, Cullen MJ, et al. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J Pharmacol Exp Ther 2004;311:547–59
   PubMed Web of Science ®Google Scholar
• Bateson AN. The benzodiazepine site of the GABAA receptor: an old target with new potential? Sleep Med 2004 5 Suppl 1:S9–15
   PubMedGoogle Scholar
• Mohler H, Fritschy JM, Crestani F, Hensch T, Rudolph U. Specific GABA(A) circuits in brain development and therapy. Biochem Pharmacol 2004;68:1685–90
   Google Scholar
• Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003;26:261–82
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006;46:1469–80
   PubMed Web of Science ®Google Scholar
• Wolschrijn H, De Gier JJ, De Smet PAGM. Drugs and driving new categorization system for medicinal drugs. Maastricht: Institute for Drugs, Safety and Behavior, 1991. Report No.: IGVG 91–124
   Google Scholar
• Hindmarch I, Patat A, Stanley N, et al. Residual effects of zaleplon and zolpidem following post-bedtime administration five hours to one hour before awakening. Hum Psychopharmacol 2001;16:159–67
   PubMed Web of Science ®Google Scholar
• Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 2002; 22:576–83
   PubMed Web of Science ®Google Scholar
• Danjou P, Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 1999;48:367–74
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Patat A, Stanley N, et al. Residual effects of zaleplon and zolpidem following post-bedtime administration five hours to one hour before awakening. Hum Psychopharmacol 2001;16:159–67
   PubMed Web of Science ®Google Scholar
• Erman MK, Erwin CW, Gengo FM, et al. Comparative efficacy of zolpidem and temazepam in transient insomnia. Hum Psychopharmacol 2001;16:169–76
   PubMed Web of Science ®Google Scholar
• Vermeeren A, Danjou PE, O’Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 1998;(13 Suppl 2):S98–107
   Google Scholar
• Vermeeren A, Riedel WJ, van Boxtel MP, et al. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002;25:224–31
   PubMed Web of Science ®Google Scholar
• Volkerts ER, O’Hanlon JF. Residual effects on real car driving performance: zopiclone versus flunitrazepam and nitrazepam [Dutch with English summary and legends]. J Drug Ther Res 1988;13:111–4
   Web of Science ®Google Scholar
• Edinger JD, Fins AI, Goeke JM, et al. The empirical identification of insomnia subtypes: a cluster analytic approach. Sleep 1996;19:398–411
   PubMed Web of Science ®Google Scholar
• Hohagen F, Kappler C, Schramm E, et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening – temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551–4
   PubMed Web of Science ®Google Scholar
• Ohayon MM, Roth T. What are the contributing factors for insomnia in the general population? J Psychosom Res 2001;51:745–55
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Browman KE, Monk TH, et al. Napping and 24-hour sleep/wake patterns in healthy elderly and young adults. J Am Geriatr Soc 1992;40:779–86
   PubMed Web of Science ®Google Scholar
• Ganguli M, Reynolds CF, Gilby JE. Prevalence and persistence of sleep complaints in a rural older community sample: the MoVIES project. J Am Geriatr Soc 1996;44:778–84
   Google Scholar
• Maggi S, Langlois JA, Minicuci N, et al. Sleep complaints in community-dwelling older persons: prevalence, associated factors, and reported causes. J Am Geriatr Soc 1998;46:161–8
   PubMed Web of Science ®Google Scholar
• Huang YL, Liu RY, Wang QS, et al. Age-associated difference in circadian sleep-wake and rest-activity rhythms. Physiol Behav 2002;76:597–603
   PubMed Web of Science ®Google Scholar
• Bliwise DL. Sleep in normal aging and dementia. Sleep 1993;16:40–81
   PubMed Web of Science ®Google Scholar
• Roehrs T, Zorick F, Roth T. 2000. Transient and short-term insomniacs. In: Kryger M, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine, 3rd edn. Philadelphia: W. B. Saunders, p 624–32
   Google Scholar
• Foster AC, Pelleymounter MA, Cullen MJ, et al. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J Pharmacol Exp Ther 2004;311:547–59
   PubMed Web of Science ®Google Scholar
• Sullivan SK, Petroski RE, Verge G, et al. Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor. J Pharmacol Exp Ther 2004;311:537–46
   PubMed Web of Science ®Google Scholar
• Jochelson P, Chen TK, Farber R, Campbell B. Lack of pharmacological and pharmacokinetic tolerance following repeat dosing of indiplon (NBI-34060). Poster presentation at the 17th annual meeting of the Associated Professional Sleep Societies. Chicago, Il, June 3–8, 2003
   Google Scholar
• Madan A, Fisher A, Jin L, et al. In vitro metabolism of indiplon and an assessment of its drug interaction potential. Xenobiotica. 2007;37:736–52
   PubMed Web of Science ®Google Scholar
• Corrigan B, Abel B, Hershberger E, et al. Indiplon with warfarin, theophylline and digoxin: Lack of pharmacokinetic interactions. J Clin Pharmacol. 2005;45:1077
   Web of Science ®Google Scholar
• Jochelson P, Chen TK, Farber R, et al. Lack of pharmacological and pharmacokinetic tolerance following repeat dosing of indiplon (NBI-34060). Sleep 2003;26:A85
   Web of Science ®Google Scholar
• Zolpidem prescribing information. Available at: http://www.sanofi-synthelabo.us/products/pi_ambien/pi_ambien.html [Last accessed on 8 August 2007]
   Google Scholar
• Eszopiclone prescribing information. Available at: http://www.lunesta.com/PostedApprovedLabelingText.pdf [Last accessed on 8 August 2007]
   Google Scholar
• Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York: The Psychological Corporation, 1955
   Google Scholar
• Jones B, Kenward MG. Design and analysis of cross-over trials. Monographs on Statistics and Applied Probability, No. 34. New York, NY: Chapman and Hall, 1993
   Google Scholar
• Hutchison TA, Shahan DR, Anderson ML (eds). DRUGDEX System, zopiclone. MICROMEDEX, Inc., Englewood, Colorado
   Google Scholar
• Roth T, Zammit GK, Scharf MB, Farber R. Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep. Sleep 2007;30:1731–8
   PubMed Web of Science ®Google Scholar